
Seragon is a research-based biopharmaceutical company focused on innovating cutting-edge discoveries in biotechnology and medicine. The company aims to develop long-term solutions for human and animal life by focusing on areas such as aging, metabolism, AI bioinformatics, gene therapy, and immunology. Seragon integrates emerging technologies like Artificial Intelligence and genomic sequencing into its research to optimize its pipeline for targeted treatments and therapies. The company's mission is to create lifelong value for human and animal health and make personalized health accessible on a global scale. Seragon is headquartered in Irvine, California.

Seragon is a research-based biopharmaceutical company focused on innovating cutting-edge discoveries in biotechnology and medicine. The company aims to develop long-term solutions for human and animal life by focusing on areas such as aging, metabolism, AI bioinformatics, gene therapy, and immunology. Seragon integrates emerging technologies like Artificial Intelligence and genomic sequencing into its research to optimize its pipeline for targeted treatments and therapies. The company's mission is to create lifelong value for human and animal health and make personalized health accessible on a global scale. Seragon is headquartered in Irvine, California.
Headquarters: Irvine, California
Sector: Biopharmaceuticals / Biotechnology
Focus: Genomics, AI-enabled bioinformatics, diagnostics, and longevity
Founder: Richard Heyman (founder; past President & CEO)
Funding: Series A (lead: OrbiMed); investors include Aisling Capital and venBio Partners; total reported $30,000,000
Exit: Acquired by Genentech
Personalized medicine, genomic diagnostics, and longevity/health optimization
Biopharmaceuticals / Biotechnology
Series A listed with OrbiMed as lead investor; company was later acquired by Genentech.
“Series A led by OrbiMed; investors include Aisling Capital and venBio Partners”